RxDoctor Payments Data

Sara Tabtabai, MD

Advanced Heart Failure and Transplant Cardiology · Hartford, CTNPI 1346477833

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,363 of the $9,018 with a category attached, or 92.7%. Novo Nordisk accounts for 65.3% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $5,888, 2.1 times the $2,811 reported in 2019.

$9,018in general payments, 2019–2025

Across 19 payments — averaging $474.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$6K
  • Alnylam Pharmaceuticals Inc.$3K
  • Abbott$217
  • Pfizer$132
  • Novartis$53
  • Amgen$41
  • plus $102 from 6 others

What the payments were for

  • Consulting fees$8,36393%
  • Food & beverage$6427%
  • Education$140%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,632
Medicare patients
271
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis18$422,838
JardianceEmpagliflozin32$48,719
EntrestoSacubitril/Valsartan14$17,653
Metoprolol Succinate44$526
Spironolactone46$242
Rosuvastatin Calcium20$196
Hydralazine Hcl13$155
Losartan Potassium15$150
Carvedilol19$137
Furosemide20$85
Amlodipine Besylate14$55
Atorvastatin Calcium11$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$132$422,83818 claims
NovartisEntresto$53$17,65314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →